Can postreatment free psa ratio be used to predict adverse outcomes in recurrent prostate cancer?

To assess whether free PSA ratio (FPSAR) at biochemical recurrence (BCR) can predict metastasis, castrate-resistant PCa (CRPC), and cancer-specific survival (CSS), following therapy for localized disease.